F10 and dementia: Additionally, NOACs hinder thrombin function by inhibiting its function (dabigatran) or generation (factorXa inhibitors, e.g., apixaban and rivaroxaban), while thrombin plays a critical role as a dementia‐related intermediary of cognitive and neurological impairment; therefore, administering NOACs may help to maintain vascular integrity and cerebral blood flow, potentially mitigating neurocognitive impairment caused by vascular disease.34